Please assess the completion status of the following clinical trial:

Trial Title: Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Renal allograft recipients who received a steroid-sparing immunosuppression protocol with rabbit anti-thymocyte globulin (Thymoglobulin) induction~* Patient must have previously enrolled in protocol entitled The use of urinary PCR test to help detect rejection in kidney transplant patients~* Recipients must agree to undergo all standard post-transplant protocol biopsies~* Recipients must be at least 3 months post-transplant and the three most recent urinary profiles must demonstrate immunologic quiescence as determined by measurement of Granzyme B and Perforin copy numbers~* Patient must provide informed consent to participate in the research study~Exclusion Criteria:~* Patient is a high-risk recipient (defined as peak or current PRA \>50% or a re-transplant recipient who lost prior graft within 1 year due to immunologic reasons)~* Patients who require maintenance steroids for another medical condition (such as asthma)~* Patients who are taking less than 1 gram/day of mycophenolate mofetil~* Multiple organ transplant recipients (such as kidney-pancreas)~* Patients with one or more acute rejection episodes within the first 3 months after transplant~* Three-month protocol biopsy showing clinical acute rejection (BANFF grade 1a or higher)~* Patient with documented or suspected non-compliance with transplant medications in the first 3 months after transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (6 to 8 ng/mL) (Type: ACTIVE_COMPARATOR): Target tacrolimus trough concentration of 6 to 8 ng/mL
- Arm 2 (3 to 5 ng.mL) (Type: ACTIVE_COMPARATOR): Target tacrolimus trough concentration of 3 to 5 ng/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).